Non-Small Cell Lung Cancer: New Treatment Study

We are testing new investigational treatments for patients with previously treated stage IV non-small cell lung cancer. The study aims to evaluate how well these treatments work and their safety.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Docetaxel
Docetaxel is a chemotherapy substance used to treat various cancers by stopping cancer cells from dividing.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Ifinatamab Deruxtecan
Raludotatug Deruxtecan

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Charite Universitaetsmedizin Berlin KöR
Medizinische Klinik mit Schwerpunkt Infektiologie/Pneumologie
Berlin, Germany
Universitaetsklinikum Tuebingen AöR
Medizinische Klinik VIII
Tübingen, Germany
Thoracic General Hospital Of Athens I Sotiria
3rd Department of Internal Medicine
Athens, Greece

Sponsor: Merck Sharp & Dohme LLC
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.